Family urges NHS to approvaecancer treatment that could offer ‘normal life’ | The IndependentNotifications can be managed in browser preferences.Jump to contentIndependentSwipe for next articleIndependent Bulletin homepageDownload our appAllNewsSportCultureLifestyleElla PickoverFriday 06 March 2026 00:37 GMTJones tarted taking zanidatamab as part of a clinical trial in January 2025 (PA Media)The family of Huw Jones, who died from bile duct cancer, is campaigning for the NHS to approve a new treatment called zanidatamab, which significantly improved his quality of life.Jones, from north Wales, was diagnosed with stage 4 cholangiocarcinoma and started taking zanidatamab in a clinical trial, allowing him to spend a year with his family after his son's birth.NICE, the NHS's spending watchdog, initially rejected the targeted treatment for widespread use but is scheduled to reassess further evidence in March.Another patient, NHS surgeon Gareth Honeybone, also experienced significant benefits from zanidatamab in a clinical trial, with scans showing his tumour is no longer visible.Charities and patients emphasise that zanidatamab offers longer life and improved quality of life for those with HER2-positive bile duct cancer, a condition with very poor survival rates.In fullNHS urged to approve new treatment for aggressive cancer after tumours shrink in sizeThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in